Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1185 | Obesity | ICEECE2012

Efficacy of orlistat vs placebo in the improvement of lipid profile among overweight and obese patients: a meta-analysis

Malong C. , Delgado J. , Cunanan E.

Background: According to the 6th National Nutrition Health Survey, the Filipino is generally unfit, with increasing incidences of major risk factors for cardiovascular disease like hypertension, abnormal lipid profile, obesity and diabetes over the last 5 years. Orlistat, a lipase inhibitor is one of the medications used to facilitate weight loss in obese patients. Given that weight loss is known to be associated with an improvement in the serum lipid profile, concurrent impro...

ea0029p1384 | Pituitary Clinical | ICEECE2012

Prevalence and incidence of pituitary adenomas; a population based study in Malta

Gruppetta M. , Mercieca C. , Vassallo J.

Context: Epidemiological data is important to correctly quantify the extent of disease and needed health care resources. There are no reports on both incidence and prevalence rates for pituitary adenomas (PAs) together in the same population.Objective: The objective of the study was to establish the prevalence and incidence of pituitary adenomas with in-depth analysis of their various subtypes in a well defined population.Design: T...

ea0029p1392 | Pituitary Clinical | ICEECE2012

Permanent panhypopituitarism is a rare complication of acute bacterial sinusitis

Lavan A. , Hannon M. , O'Brien M. , Thompson C.

Permanent pan-anterior hypopituitarism is a rare complication of bacterial sinusitis, with only six cases reported worldwide. However, all were reported before the advent of MR imaging and most did not have what is now regarded as gold standard evaluation of pituitary function. Also, all previous cases noted an interval of months between resolution of sinusitis and development of hypopituitarism. We report two cases of previously healthy Caucasian adults who developed pan-ante...

ea0029p1393 | Pituitary Clinical | ICEECE2012

Carboplatin is a novel cause of the syndrome of inappropriate antidiuresis

O'Brien M. , Hannon M. , Lavan A. , Thompson C.

The syndrome of inappropriate antidiuresis (SIAD) is characterised by plasma hyponatraemia and plasma hypoosmolality with a high urinary sodium in a clinically euvolaemic patient. We describe only the second reported case of SIAD due to carboplatin administration, with consequent acute severe hyponatraemia.A 61-year-old lady with no background history of note received neoadjuvant carboplatin and paclitaxel for stage III ovarian carcinoma. Five days after...

ea0029p1396 | Pituitary Clinical | ICEECE2012

The clinical outcome of pituitary adenomas in the cavernous sinus

Marathe C. , Irish G. , Torpy D.

Introduction: Pituitary adenomas with cavernous sinus involvement (CSI) are associated with serious clinical sequelae but are often incompletely excised during surgery. Contradictory viewpoints exist regarding management of residual tumors in the cavernous sinus with some authors suggesting use of adjuvant radiotherapy post-operatively for long term tumor control. But radiotherapy has been associated with hypopituitarism and increased mortality due to cerebrovascular causes. W...

ea0029p1528 | Pituitary Clinical | ICEECE2012

Progressive combined pituitary hormone deficiency produced by Prop1 gene mutation

Ghervan C. , Stroe M. , Young J.

Introduction: The appearance and normal development of the anterior pituitary gland requires several signalling molecules and specific transcription factors, such as PROP1, POUF1, HESX1/RPX, LHX3, LHX4, PITX2, T-PIT, SOX2 and SOX 3. Gene mutations of these pituitary transcription factors may lead to different degrees of combined pituitary hormone deficiency (CPHD) associated or not with morphological changes of the hypothalamic–pituitary region.Mate...

ea0029p1531 | Pituitary Clinical | ICEECE2012

Hyperprolactinemia: etiology, diagnosis and therapeutic aspects

Crista C. , Vlazan A. , Scheau M. , Racolta A.

The complex etiology of hyperprolactinemia was represented, in our study group (426 cases hospitalized during the period 2000 – 2010; F/M ratio=372/54; age (years)=40.29±15.57), by the following entities: prolactin-secreting pituitary tumors (11.50%), growth hormone and prolactin-secreting pituitary tumors (1.64%), pituitary stalk compression (7.98%), primary myxedema (41.08%), polycystic ovary syndrome – PCOS (24.65%), iatrogenesis (8.69%) and chronic renal ins...

ea0029p1547 | Steroid metabolism + action | ICEECE2012

Conversion of 7α-hydroxyDHEA into 7-ketoDHEA: Role of type 2 11β-hydroxysteroid dehydrogenase

Ngo-Duy C. , Labrie F. , Luu-The V.

It has been suggested that DHEA metabolites, especially 7-hydroxy and/or 7-keto derivatives could possess anti-inflammatory activity and enhance immune, cognitive and metabolic functions in rodents. It is thus important to elucidate the exact pathway (s) leading to the formation of these metabolites. While the role of cytochrome P450 CYP7B1 in the transformation of DHEA into 7α-OHDHEA is well recognized, the role of type 1 11β-hydroxysteroid dehydrogenase (11β-H...

ea0029p1548 | Steroid metabolism + action | ICEECE2012

Steroid derivatives as pure antagonists of the androgen receptor

Gauthier S. , Martel C. , Labrie F.

Introduction: While the androgens of testicular origin (representing about 50% of total androgens in men over 50 years) can be completely eliminated by surgical or medical castration with GnRH (gonadotropin-releasing hormone) agonists or antagonists, the antiandrogens currently available as blockers of androgen binding to the androgen receptor (AR), namely bicalutamide (BICA), flutamide (FLU) and nilutamide have too weak affinity to completely neutralize the 50% of androgens m...

ea0029p1675 | Thyroid (non-cancer) | ICEECE2012

Measurement of TSH, FT4 and FT3 with immunoassays based on LOCI technology

Lepoutre T. , Daumerie C. , Gruson D.

Background: Measurements of TSH, free tetraiodothyronin (FT4) and triiodothyronin (FT3) are essential to achieve assessment of thyroid function. Luminescent Oxygen Channelling Immunoassays (LOCI) have recently been developed for the measurement of biomarkers of thyroid function. Such homogeneous immunoassays allow a faster delivery of the results. The aim of our study were therefore to determine the reference values for LOCI TSH, FT4 and FT<sub...